Published in Oncotarget on March 29, 2016
MicroRNAs in extracellular vesicles: potential cancer biomarkers. J Hum Genet (2016) 0.81
Obstacles and opportunities in the functional analysis of extracellular vesicle RNA - an ISEV position paper. J Extracell Vesicles (2017) 0.80
Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. Int J Clin Oncol (2017) 0.79
Vesicle-MaNiA: extracellular vesicles in liquid biopsy and cancer. Curr Opin Pharmacol (2016) 0.78
Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. J Cell Mol Med (2016) 0.77
miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition. Front Pharmacol (2016) 0.77
Extracellular miRNAs as biomarkers in cancer. Food Chem Toxicol (2016) 0.75
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. Oncotarget (2016) 0.75
The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer. Mol Cancer (2017) 0.75
Tumor Microenvironment Modulation via Gold Nanoparticles Targeting Malicious Exosomes: Implications for Cancer Diagnostics and Therapy. Int J Mol Sci (2017) 0.75
The roles and implications of exosomes in sarcoma. Cancer Metastasis Rev (2016) 0.75
Comparative analysis of microRNA expression profiles between A549, A549/DDP and their respective exosomes. Oncotarget (2017) 0.75
eTumorType, An Algorithm of Discriminating Cancer Types for Circulating Tumor Cells or Cell-free DNAs in Blood. Genomics Proteomics Bioinformatics (2017) 0.75
The miR-200 family in ovarian cancer. Oncotarget (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 37.10
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet (2010) 15.87
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev (2008) 15.01
MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol (2008) 11.46
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 10.56
Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res (2005) 9.80
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics (2009) 4.27
The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep (2010) 4.05
Ovarian cancer. Lancet (2014) 3.80
Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol (2014) 2.87
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev (2013) 2.46
Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene (2011) 2.42
A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol (2009) 2.26
The heterogeneity of ovarian cancer. Arch Gynecol Obstet (2014) 2.09
The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol (2011) 2.03
Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics (2015) 1.65
Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis (2012) 1.57
Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell (2012) 1.49
Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles (2015) 1.32
Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer (2012) 1.27
The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget (2015) 1.18
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med (2014) 1.13
Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res (2014) 1.12
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat (2014) 1.08
MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget (2014) 1.07
Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol (2012) 1.07
Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol (2013) 1.06
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget (2014) 1.05
Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett (2014) 1.02
Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol Obstet (Sunnyvale) (2013) 1.01
Data Normalization Strategies for MicroRNA Quantification. Clin Chem (2015) 1.00
Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol (2013) 0.98
Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clin Transl Oncol (2015) 0.92
MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer. Oncotarget (2015) 0.84
Diverse functions of miR-373 in cancer. J Transl Med (2015) 0.82
MicroRNA profiling of exosomes isolated from biofluids and conditioned media. Methods Mol Biol (2014) 0.82
The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. Int J Mol Sci (2015) 0.81
The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Rev Mol Diagn (2015) 0.80
Plasma microRNA signature is associated with risk stratification in prostate cancer patients. Int J Cancer (2017) 0.75